CYMABAY THERAPEUTICS INC OM has a consensus price target of $19.37, established from looking at the 54 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Leerink Partners, and LifeSci Capital on February 29, 2024, February 20, 2024, and February 14, 2024. With an average price target of $21.67 between HC Wainwright & Co., Leerink Partners, and LifeSci Capital, there's an implied -33.29% downside for CYMABAY THERAPEUTICS INC OM from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/29/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 0.06% | HC Wainwright & Co. | Ed Arce | → $32.5 | Reiterates | Neutral → Neutral | Get Alert |
02/20/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 0.06% | Leerink Partners | Thomas Smith | → $32.5 | Downgrade | Outperform → Market Perform | Get Alert |
02/14/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | — | LifeSci Capital | Cory Jubinville | — | Downgrade | Outperform → Market Perform | Get Alert |
02/14/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 0.06% | UBS | Eliana Merle | $25 → $32.5 | Downgrade | Buy → Neutral | Get Alert |
02/14/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 0.06% | Piper Sandler | Yasmeen Rahimi | $33 → $32.5 | Downgrade | Overweight → Neutral | Get Alert |
02/13/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 0.06% | B. Riley Securities | Mayank Mamtani | $29 → $32.5 | Downgrade | Buy → Neutral | Get Alert |
02/13/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | — | BTIG | Julian Harrison | — | Downgrade | Buy → Neutral | Get Alert |
02/13/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | — | HC Wainwright & Co. | Ed Arce | — | Downgrade | Buy → Neutral | Get Alert |
02/13/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 0.06% | Raymond James | Steven Seedhouse | $32.5 → $32.5 | Downgrade | Strong Buy → Market Perform | Get Alert |
02/13/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 0.06% | Cantor Fitzgerald | Kristen Kluska | → $32.5 | Downgrade | Overweight → Neutral | Get Alert |
02/13/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | — | JonesTrading | Sean Kim | — | Downgrade | Buy → Hold | Get Alert |
02/12/2024 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | — | William Blair | Andy Hsieh | — | Downgrade | Outperform → Market Perform | Get Alert |
12/15/2023 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | -13.79% | HC Wainwright & Co. | Ed Arce | $24 → $28 | Maintains | Buy | Get Alert |
11/08/2023 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | -26.11% | Cantor Fitzgerald | Kristen Kluska | $23 → $24 | Maintains | Overweight | Get Alert |
11/08/2023 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | -26.11% | HC Wainwright & Co. | Ed Arce | $21 → $24 | Maintains | Buy | Get Alert |
11/08/2023 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 4.68% | Raymond James | Steven Seedhouse | $33 → $34 | Maintains | Strong Buy | Get Alert |
11/06/2023 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | 1.6% | Piper Sandler | Yasmeen Rahimi | $19 → $33 | Maintains | Overweight | Get Alert |
09/26/2023 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | -23.03% | UBS | Eliana Merle | $18 → $25 | Maintains | Buy | Get Alert |
09/08/2023 | CBAY | Buy Now | CymaBay Therapeutics | $32.48 | -32.27% | B. Riley Securities | Mayank Mamtani | $16 → $22 | Maintains | Buy | Get Alert |
The latest price target for CYMABAY THERAPEUTICS INC OM (NASDAQ: CBAY) was reported by HC Wainwright & Co. on February 29, 2024. The analyst firm set a price target for $32.50 expecting CBAY to rise to within 12 months (a possible 0.06% upside). 41 analyst firms have reported ratings in the last year.
The latest analyst rating for CYMABAY THERAPEUTICS INC OM (NASDAQ: CBAY) was provided by HC Wainwright & Co., and CYMABAY THERAPEUTICS INC OM reiterated their neutral rating.
There is no last upgrade for CYMABAY THERAPEUTICS INC OM.
The last downgrade for CYMABAY THERAPEUTICS INC OM happened on February 20, 2024 when Leerink Partners changed their price target from N/A to $32.5 for CYMABAY THERAPEUTICS INC OM.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CYMABAY THERAPEUTICS INC OM, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CYMABAY THERAPEUTICS INC OM was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
While ratings are subjective and will change, the latest CYMABAY THERAPEUTICS INC OM (CBAY) rating was a reiterated with a price target of $0.00 to $32.50. The current price CYMABAY THERAPEUTICS INC OM (CBAY) is trading at is $32.48, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.